In a bid to strengthen its presence in the US nasal drug delivery market, Strides Pharma Global Pte. Limited—a wholly owned Singapore subsidiary of Strides Pharma Science—has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. Under the agreement, the two companies will jointly develop and submit filings for multiple nasal spray products targeting a variety of therapeutic areas in the United States. Specific product details and contract value remain confidential.

Strides’ investment in its US manufacturing facility aligns with its ongoing focus on expanding into the nasal spray domain. According to Aditya Kumar, Executive Director of Business Development at Strides, this collaboration builds on the company’s substantial progress in the area and complements its strategic ambitions. He noted that “Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market capabilities, enabling us to expedite the rollout of nasal spray offerings in the US.”

Kenox Pharmaceuticals, a rapidly expanding contract development and manufacturing organisation specialising in orally inhaled and nasal drug products, will bring its technical know-how to the table—helping to accelerate the delivery of affordable, high-quality nasal therapies for US patients. Chief Executive Officer Sitaram Velaga praised the partnership as a significant milestone for Kenox, validating its OINDP expertise and its mission to make important drug products more accessible globally.

This alliance underscores Strides’ commitment to expanding its nasal spray portfolio and improving patient access to essential treatments in one of its most strategic markets.